Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma

  • Yazmin Odia
  • , Carl Koschmann
  • , Nicholas A. Vitanza
  • , Peter De Blank
  • , Dolly Aguilera
  • , Jeffrey Allen
  • , Doured Daghistani
  • , Matthew Hall
  • , Ziad Khatib
  • , Cassie Kline
  • , Tobey Macdonald
  • , Sabine Mueller
  • , Shamia L. Faison
  • , Joshua E. Allen
  • , Odin J. Naderer
  • , Samuel C. Ramage
  • , Rohinton S. Tarapore
  • , Susan Lynne McGovern
  • , Soumen Khatua
  • , Wafik Zaky
  • Sharon L. Gardner

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Pages (from-to)S155-S164
JournalNeuro-Oncology
Volume26
Issue numberSupplement_2
DOIs
StatePublished - Apr 1 2024
Externally publishedYes

ASJC Scopus Subject Areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Keywords

  • dordaviprone
  • dose optimization
  • H3 K27M mutation
  • ONC201

Cite this